clinical trial · NCT06488170
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
Almirall, S.A.·—·active not recruiting·n = 42
Plaque PsoriasisTildrakizumab
brief summary
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the summary of product characteristics (SmPC).
started
Apr 4, 2024
primary completion
Jan 1, 2026
completion
Jan 1, 2026
last updated
Jun 24, 2025
official title
Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting - Light Version
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol